PolicyBrief (Issue 14): Cetuximab as an adjuvant therapy for metastatic colorectal cancer (mCRC): Does the high cost outweigh the benefit for saving patient’s life?
Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National D ...อ่านต่อ